Results for this period
Third quarter1 August 2025 to 30 April 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to growth in sales of the core Neumo series and new products, the expansion of sales channels, and the overseas rollout of Pharma GABA. Meanwhile, advertising and promotional expenses and research and development expenses increased to foster new products.
No applicable matters. Stated as “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 August 2025 to 30 April 2026 |
| Net Sales | ¥48,555 million (YoY +3.7%) |
| Operating profit | ¥-1,430 million |
| Ordinary income | ¥-1,545 million |
| Profit attributable to owners of the parent | ¥-1,061 million |
| Net income per share | -¥36.67 |
| Equity ratio | End of the current fiscal period 28.9 / End of previous period 35.4 |
| Total assets | ¥34,856 million |
| Net assets | ¥10,084 million |
| Cash flows from operating activities | ¥-3,557 million |
| Cash flows from investing activities | ¥-680 million |
| Cash flows from financing activities | ¥3,849 million |
| Cash and cash equivalents at end of period | ¥8,665 million |
| Full-year earnings forecast | Net Sales ¥67,000 million (YoY +2.7%) / Operating profit ¥2,000 million (YoY -15.5%) / Ordinary income ¥2,000 million (YoY -21.7%) / Net income ¥1,500 million (YoY +307.6%) |
| Annual Dividend Forecast | ¥25 → ¥25（0.0%） |
| Segment revenue | B2B Business ¥5,560 million (YoY -4.7%) / B2C Business ¥42,734 million (YoY +4.9%) / Biomedical business ¥230 million (YoY -4.0%) |
| Segment profit | B2B Business ¥858 million (YoY -2.7%) / B2C Business ¥-342 million / Biomedical business ¥-473 million |
| Depreciation and amortization | ¥510 million |
| Impairment loss | No impairment loss was recorded for the period. There were no applicable matters concerning impairment losses on fixed assets or other information for each reporting segment. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥4 million / Extraordinary loss Loss on sale of shares of subsidiaries and affiliates ¥117 million |
| Disclosure regarding the going concern assumption | No applicable matters. Stated as “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 29,079,000 Shares |
| Treasury Shares at Period-End | 35,623 Shares |
| Factors Behind Changes in Business Performance | Revenue increased due to growth in sales of the core Neumo series and new products, the expansion of sales channels, and the overseas rollout of Pharma GABA. Meanwhile, advertising and promotional expenses and research and development expenses increased to foster new products. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to sales of new products and the Neumo series, as well as the expansion of sales channels. Meanwhile, expenses increased as advertising and promotional activities were strengthened and investment in research and development was made to foster new products.